Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 4 Next >
Myriad Genetics Earns 2025 Great Place To Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Inducement Awards
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Senior Leadership Transition
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.